Vitamin D and Multiple Sclerosis: What Genetics Reveals About Disease Risk

Multiple sclerosis (MS) is a chronic autoimmune and neurological disorder in which immune-mediated damage to myelin disrupts communication within the central nervous system. Although genetic susceptibility contributes substantially to MS risk, environmental factors are also believed to influence disease development. One particularly important candidate is vitamin D. Epidemiological research has repeatedly shown that MS is more common at higher latitudes, where exposure to ultraviolet radiation is generally lower, and that individuals with lower circulating concentrations of 25-hydroxyvitamin D (25OHD), the principal clinical marker of vitamin D status, tend to have a greater risk of MS. However, conventional observational studies cannot establish whether vitamin D deficiency itself contributes to disease development. People with early or undiagnosed MS may spend less time outdoors and consequently have lower vitamin D levels, creating reverse causation, while lifestyle, socioeconomic, dietary, or other biological factors may confound the relationship. To address this problem, Mokry and colleagues conducted a Mendelian randomization study designed to investigate whether lifelong genetically reduced vitamin D concentrations are associated with increased susceptibility to MS.

Mendelian Randomization as a Tool for Causal Inference
The central methodological strength of the study lies in its use of Mendelian randomization (MR), an epidemiological approach that employs inherited genetic variants as proxies, or instrumental variables, for modifiable biological exposures. Because alleles are allocated at conception and remain largely unchanged throughout life, their distribution is generally less affected by behavioral confounding or reverse causation than measured vitamin D concentrations. The researchers selected four single nucleotide polymorphisms (SNPs) that had previously reached genome-wide significance for their association with circulating 25OHD in the SUNLIGHT consortium, which included 33,996 individuals of European ancestry. These variants were rs2282679 in GC, rs12785878 near DHCR7, rs10741657 near CYP2R1, and rs6013897 in CYP24A1. Importantly, these genes participate in distinct components of vitamin D biology: GC encodes the principal vitamin D-binding protein, DHCR7 influences the availability of a precursor required for cutaneous vitamin D synthesis, CYP2R1 contributes to hepatic 25-hydroxylation, and CYP24A1 participates in vitamin D inactivation. The pathway diagram on page 8 of the article illustrates how these genetic loci are positioned across vitamin D synthesis, transport, activation, and metabolism, strengthening their biological plausibility as instruments for vitamin D status.

Establishing the Genetic Influence on Vitamin D Levels
Before examining MS risk, the investigators confirmed that the selected genetic variants were meaningfully associated with vitamin D concentrations. Using data from 2,347 participants in the Canadian Multicentre Osteoporosis Study, they estimated the effect of each SNP on natural-log-transformed 25OHD levels while adjusting for major determinants of vitamin D status, including age, sex, body mass index, and season of measurement. The combined number of 25OHD-decreasing alleles was strongly associated with lower circulating vitamin D, producing an F-statistic of 49.7 and a highly significant p-value of 2.4 × 10⁻¹². The allele score explained approximately 2.44% of population-level variation in 25OHD. Although this proportion may appear modest, it is sufficient for genetic instrumental-variable analysis because the relevant requirement is that the instruments demonstrate a statistically robust relationship with the exposure. The box plot presented on page 10 shows a clear downward trend in vitamin D concentrations as the number of vitamin-D-lowering alleles increases, with a non-parametric trend p-value of 3.3 × 10⁻¹⁹. This dose-related genetic pattern supports the validity of the selected SNPs as instruments representing lifelong differences in vitamin D status.

Genetically Lower Vitamin D Was Associated With Substantially Higher MS Risk
The investigators next examined the relationship between these vitamin-D-associated variants and MS using large genetic datasets from the International Multiple Sclerosis Genetics Consortium. The principal dataset included up to 14,498 MS cases and 24,091 healthy controls of European ancestry. When the effects of all four genetic variants were combined in a fixed-effects Mendelian randomization model, each one-standard-deviation decrease in natural-log-transformed 25OHD was associated with approximately a twofold increase in the odds of developing MS, with an odds ratio of 2.02, a 95% confidence interval of 1.65–2.46, and a p-value of 7.72 × 10⁻¹². A random-effects model produced a very similar estimate, with an odds ratio of 2.07. The forest plot on page 11 visually demonstrates that the combined genetic estimate strongly favors greater MS risk as genetically predicted vitamin D levels decrease. Furthermore, all four vitamin-D-lowering alleles individually showed effect estimates in the direction of increased MS susceptibility, although the strength of association differed between variants. These findings substantially reinforce the hypothesis that reduced vitamin D status is not simply a consequence or correlate of MS, but may lie on a causal pathway influencing disease susceptibility.

Sensitivity Analyses Strengthened the Main Findings
A critical concern in Mendelian randomization is pleiotropy, in which a genetic variant influences the outcome through biological pathways unrelated to the exposure of interest. Population stratification can similarly produce misleading associations if allele frequencies and disease rates both vary across ancestral or geographic groups. The researchers therefore conducted several sensitivity analyses. The DHCR7 variant was excluded in one analysis because it demonstrated evidence of geographic population stratification, yet the association between genetically lower 25OHD and MS remained significant, with an odds ratio of 1.72 and a 95% confidence interval of 1.34–2.21. The GC variant was also excluded separately because vitamin D-binding protein may exert biological effects independent of vitamin D itself; again, the overall association remained strong. In addition, the investigators divided the instruments into variants involved primarily in vitamin D synthesis and those related to metabolism. Both pathways independently indicated increased MS susceptibility: the synthesis-related variants produced an odds ratio of 2.08, while metabolism-related variants produced an odds ratio of 1.86. These convergent findings across biologically distinct genetic mechanisms make it less likely that the principal result was driven by a single unusual locus, although the authors appropriately acknowledged that residual pleiotropy cannot be excluded completely.

Biological and Clinical Significance of the Findings
The results are biologically plausible because vitamin D has important immunomodulatory functions that may influence mechanisms relevant to autoimmunity. Previous experimental work cited by the authors indicates that vitamin D can affect immune-cell behavior and the regulation of major histocompatibility complex class II genes, including pathways already implicated in MS susceptibility. The study also attempted to translate the genetic effect into clinically recognizable vitamin D concentrations. According to the calculations in Table 5, for an individual with a 25OHD concentration of 25 nmol/L, approximately corresponding to the threshold for vitamin D deficiency, a rise to about 36.9 nmol/L represented the modeled one-standard-deviation increase associated with approximately 50% lower odds of MS. Comparable modeled increases were from 50 to 73.7 nmol/L and from 75 to 110.6 nmol/L. These figures should not, however, be interpreted as treatment targets or as proof that supplementation will reduce an individual's MS risk by exactly 50%. Mendelian randomization estimates reflect the effects of lifelong genetically influenced differences in vitamin D status, whereas supplementation generally occurs later in life and over much shorter periods. The study therefore provides evidence supporting causal relevance, but not a clinical dosing recommendation.

Implications, Limitations, and the Need for Randomized Trials
The study provides influential evidence that genetically reduced vitamin D status may increase susceptibility to multiple sclerosis, yet its conclusions must be interpreted within clearly defined limits. First, the analysis evaluated the risk of developing MS rather than the effectiveness of vitamin D in treating established disease; it therefore cannot determine whether supplementation reduces relapse frequency, neurological disability, or disease progression after diagnosis. Second, the genetic datasets primarily included individuals of European ancestry, meaning that the magnitude of the association cannot automatically be generalized to populations with different genetic backgrounds. Third, Mendelian randomization depends on assumptions regarding the absence of important pleiotropic pathways and other sources of bias, and these assumptions can never be verified with complete certainty. Nevertheless, the persistence of the association across several sensitivity analyses, together with the biological relevance of the genetic instruments and the large sample sizes involved, makes the findings scientifically compelling. The principal contribution of the study is therefore not the demonstration that vitamin D supplements prevent MS, but the provision of strong genetic evidence that long-term vitamin D status may participate in the causal architecture of MS susceptibility. As the authors conclude, appropriately designed long-term randomized controlled trials are required to determine whether maintaining adequate vitamin D levels can meaningfully delay or prevent MS onset in individuals at elevated risk.

Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.

References:
Mokry, L. E., Ross, S., Ahmad, O. S., Forgetta, V., Smith, G. D., Leong, A., ... & Richards, J. B. (2015). Vitamin D and risk of multiple sclerosis: a Mendelian randomization study. PLoS medicine, 12(8), e1001866.